United States· US:0024-5761_dd3cca75-32f2-4e6d-8121-20f47e101495
Soliqua 100/33
A insulin glargine and lixisenatide product containing insulin glargine; lixisenatide, registered in United States by Sanofi-Aventis U.S. LLC. The same ATC class is registered in 10 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Insulin glargine and lixisenatide is registered in 10 of 19 countries.
Countries holding a registration under ATC A10AE54 (insulin glargine and lixisenatide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 6 of them publish a price we can compare per daily dose
Insulin glargine and lixisenatide · ATC A10AE54
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- INSULIN GLARGINE; LIXISENATIDE
- Manufacturer
- Sanofi-Aventis U.S. LLC
- Country
- United States (US)
- ATC code
- A10AE54
- ATC class
- Insulin glargine and lixisenatide
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc110024-5761-01
- ndc110024-5761-05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin glargine and lixisenatide in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSULIQUASanofi Winthrop Industrie, Gentilly
- SwitzerlandSuliqua 100/33, solution injectableSanofi-Aventis (Suisse) SA
- SpainSULIQUA 100 UNIDADES/ML + 33 MICROGRAMOS/ML SOLUCION INYECTABLE EN PLUMA PRECARGADASanofi Winthrop Industrie
- FinlandSuliquaSanofi Winthrop Industrie
- United KingdomSuliqua 100units/ml / 33micrograms/ml solution for injection 3ml pre-filled SoloStar pensSanofi
- IrelandSuliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled penSanofi-Aventis Groupe
- IcelandSuliquaSanofi Winthrop Industrie
- SwedenSuliqua 100 enheter/ml+33 mikrogram/ml Injektionsvätska, lösning i förfylld injektionspennaSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Suliqua
- Liechtenstein · Suliqua
- Norway · Suliqua
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d9cad7be-d27a-4edb-b4e4-4a09e0cddab7 GET /v1/drugs/d9cad7be-d27a-4edb-b4e4-4a09e0cddab7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "100; 33",
"substance": "INSULIN GLARGINE; LIXISENATIDE",
"productndc": "0024-5761",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "U/mL; ug/mL",
"application_number": "BLA208673",
"marketing_category": "BLA"
}See everything about insulin glargine and lixisenatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.